ROS and the DNA damage response in cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Curtin, 2012, DNA repair dysregulation from cancer driver to therapeutic target, Nat. Rev. Cancer, 12, 801, 10.1038/nrc3399
Sancar, 2004, Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints, Annu. Rev. Biochem., 73, 39, 10.1146/annurev.biochem.73.011303.073723
Goldstein, 2015, The DNA damage response: implications for tumor responses to radiation and chemotherapy, Annu. Rev. Med., 66, 129, 10.1146/annurev-med-081313-121208
Ciccia, 2010, The DNA damage response: making it safe to play with knives, Mol. Cell, 40, 179, 10.1016/j.molcel.2010.09.019
McNally, 2017, Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases, Proc. Natl. Acad. Sci. USA, 114, E4782, 10.1073/pnas.1703683114
Polo, 2011, Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications, Genes Dev., 25, 409, 10.1101/gad.2021311
Aguiar, 2013, Oxidative stress and DNA lesions: the role of 8-oxoguanine lesions in Trypanosoma cruzi cell viability, PLoS Negl. Trop. Dis., 7, e2279, 10.1371/journal.pntd.0002279
Dahlgren, 1999, Respiratory burst in human neutrophils, J. Immunol. Methods, 232, 3, 10.1016/S0022-1759(99)00146-5
Zhang, 2016, ROS and ROS-Mediated Cellular Signaling, Oxid. Med. Cell Longev., 2016, 4350965, 10.1155/2016/4350965
Perry, 2010, The structural biochemistry of the superoxide dismutases, Biochim. Biophys. Acta, 1804, 245, 10.1016/j.bbapap.2009.11.004
Meitzler, 2014, NADPH oxidases: a perspective on reactive oxygen species production in tumor biology, Antioxid. Redox Signal., 20, 2873, 10.1089/ars.2013.5603
Fransen, 2012, Role of peroxisomes in ROS/RNS-metabolism: implications for human disease, Biochim. Biophys. Acta, 1822, 1363, 10.1016/j.bbadis.2011.12.001
Ziech, 2011, Reactive oxygen species (ROS)--induced genetic and epigenetic alterations in human carcinogenesis, Mutat. Res., 711, 167, 10.1016/j.mrfmmm.2011.02.015
Fan, 2018, Quantitative proteomics reveals mitochondrial respiratory chain as a dominant target for carbon ion radiation: delayed reactive oxygen species generation caused DNA damage, Free Radic. Biol. Med.
Zulato, 2018, LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and gamma-irradiation, Biochem. Pharmacol., 156, 479, 10.1016/j.bcp.2018.09.019
Ma, 2014, High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy, Sci. Transl. Med., 6, 10.1126/scitranslmed.3007154
Gonzalez, 2005, Orthomolecular oncology review: ascorbic acid and cancer 25 years later, Integr. Cancer Ther., 4, 32, 10.1177/1534735404273861
Wright, 2007, Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial, Cancer, 109, 891, 10.1002/cncr.22482
Alpha-Tocopherol BCCPSG, 1994, The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers, N. Engl. J. Med., 330, 1029, 10.1056/NEJM199404143301501
E.J. Hall, Radiobiology for the radiologist, 1973.
Conklin, 2004, Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness, Integr. Cancer Ther., 3, 294, 10.1177/1534735404270335
Marullo, 2013, Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions, PLoS One, 8, e81162, 10.1371/journal.pone.0081162
Salehi, 2018, Oxidative DNA damage induced by ROS-modulating agents with the ability to target DNA: a comparison of the biological characteristics of citrus pectin and apple pectin, Sci. Rep., 8, 13902, 10.1038/s41598-018-32308-2
Cannan, 2014, Nucleosomes suppress the formation of double-strand DNA breaks during attempted base excision repair of clustered oxidative damages, J. Biol. Chem., 289, 19881, 10.1074/jbc.M114.571588
Shokolenko, 2009, Oxidative stress induces degradation of mitochondrial DNA, Nucleic Acids Res., 37, 2539, 10.1093/nar/gkp100
Kotsantis, 2018, Mechanisms of oncogene-induced replication stress: jigsaw falling into place, Cancer Discov., 8, 537, 10.1158/2159-8290.CD-17-1461
Maya-Mendoza, 2018, High speed of fork progression induces DNA replication stress and genomic instability, Nature, 559, 279, 10.1038/s41586-018-0261-5
Halazonetis, 2008, An oncogene-induced DNA damage model for cancer development, Science, 319, 1352, 10.1126/science.1140735
Maya-Mendoza, 2015, Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress, Mol. Oncol., 9, 601, 10.1016/j.molonc.2014.11.001
Park, 2014, Novel signaling axis for ROS generation during K-Ras-induced cellular transformation, Cell Death Differ., 21, 1185, 10.1038/cdd.2014.34
Meng, 2018, DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer, Cancer Lett., 428, 104, 10.1016/j.canlet.2018.04.029
Graindorge, 2015, Singlet oxygen-mediated oxidation during UVA radiation alters the dynamic of genomic DNA replication, PLoS One, 10, e0140645, 10.1371/journal.pone.0140645
Somyajit, 2017, Redox-sensitive alteration of replisome architecture safeguards genome integrity, Science, 358, 797, 10.1126/science.aao3172
Sedletska, 2013, Replication fork collapse is a major cause of the high mutation frequency at three-base lesion clusters, Nucleic Acids Res., 41, 9339, 10.1093/nar/gkt731
Blackford, 2017, ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response, Mol. Cell, 66, 801, 10.1016/j.molcel.2017.05.015
Matsuoka, 2007, ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage, Science, 316, 1160, 10.1126/science.1140321
Sullivan, 2015, ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels, Cell Cycle, 14, 56, 10.4161/15384101.2014.973330
Valentin-Vega, 2012, Mitochondrial dysfunction in ataxia-telangiectasia, Blood, 119, 1490, 10.1182/blood-2011-08-373639
Agathanggelou, 2015, Targeting the ataxia telangiectasia mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants, Haematologica, 100, 1076
Zhou, 2013, Nrf2 is a potential therapeutic target in radioresistance in human cancer, Crit. Rev. Oncol. Hematol., 88, 706, 10.1016/j.critrevonc.2013.09.001
Gregory, 2016, ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia, Proc. Natl. Acad. Sci. USA, 113, E6669, 10.1073/pnas.1603876113
Wang, 2018, Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells, JCI Insight, 3, 10.1172/jci.insight.98096
Li, 2014, The catalytic subunit of DNA-dependent protein kinase is required for cellular resistance to oxidative stress independent of DNA double-strand break repair, Free Radic. Biol. Med, 76, 278, 10.1016/j.freeradbiomed.2014.08.019
Kozlov, 2016, Reactive oxygen species (ROS)-activated ATM-dependent phosphorylation of cytoplasmic substrates identified by large-scale phosphoproteomics screen, Mol. Cell Proteom., 15, 1032, 10.1074/mcp.M115.055723
Katsube, 2014, Most hydrogen peroxide-induced histone H2AX phosphorylation is mediated by ATR and is not dependent on DNA double-strand breaks, J. Biochem., 156, 85, 10.1093/jb/mvu021
Willis, 2013, APE2 is required for ATR-Chk1 checkpoint activation in response to oxidative stress, Proc. Natl. Acad. Sci. USA, 110, 10592, 10.1073/pnas.1301445110
Wu, 2013, ARID1A mutations in cancer: another epigenetic tumor suppressor?, Cancer Discov., 3, 35, 10.1158/2159-8290.CD-12-0361
Shen, 2015, ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors, Cancer Discov., 5, 752, 10.1158/2159-8290.CD-14-0849
Williamson, 2016, ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A, Nat. Commun., 7, 13837, 10.1038/ncomms13837
Xie, 2017, Reactive oxygen species downregulate ARID1A expression via its promoter methylation during the pathogenesis of endometriosis, Eur. Rev. Med. Pharmacol. Sci., 21, 4509
Winarto, 2017, ARID1A expression is down-regulated by oxidative stress in endometriosis and endometriosis-associated ovarian cancer, Transl. Oncogenomics, 9, 10.1177/1177272716689818
Kwan, 2016, Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells, Oncotarget, 7, 56933, 10.18632/oncotarget.10921
Lissanu Deribe, 2018, Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer, Nat. Med., 24, 1047, 10.1038/s41591-018-0019-5
Fernandez-Capetillo, 2004, H2AX: the histone guardian of the genome, DNA Repair, 3, 959, 10.1016/j.dnarep.2004.03.024
Paull, 2000, A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage, Curr. Biol., 10, 886, 10.1016/S0960-9822(00)00610-2
Rogakou, 1998, DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139, J. Biol. Chem., 273, 5858, 10.1074/jbc.273.10.5858
Bassing, 2002, Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX, Proc. Natl. Acad. Sci. USA, 99, 8173, 10.1073/pnas.122228699
Celeste, 2002, Genomic instability in mice lacking histone H2AX, Science, 296, 922, 10.1126/science.1069398
Gruosso, 2016, Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients, EMBO Mol. Med., 8, 527, 10.15252/emmm.201505891
Li, 2006, Oxidative stress induces H2AX phosphorylation in human spermatozoa, FEBS Lett., 580, 6161, 10.1016/j.febslet.2006.10.016
Lee, 2015, High expression of phospho-H2AX predicts a poor prognosis in colorectal cancer, Anticancer Res., 35, 2447
Nagelkerke, 2011, Constitutive expression of gamma-H2AX has prognostic relevance in triple negative breast cancer, Radiother. Oncol., 101, 39, 10.1016/j.radonc.2011.07.009
Chatzimichail, 2014, gamma -H2AX: a novel Prognostic marker in a prognosis prediction model of patients with early operable non-small cell lung cancer, Int. J. Genom., 2014, 160236
Kang, 2012, DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway, Cell Death Dis., 3, e249, 10.1038/cddis.2011.134
Cheng, 2006, Nox1-dependent reactive oxygen generation is regulated by Rac1, J. Biol. Chem., 281, 17718, 10.1074/jbc.M512751200
Mitsushita, 2004, The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation, Cancer Res., 64, 3580, 10.1158/0008-5472.CAN-03-3909
Koczor, 2009, Mitochondrial DNA damage initiates a cell cycle arrest by a Chk2-associated mechanism in mammalian cells, J. Biol. Chem., 284, 36191, 10.1074/jbc.M109.036020
Chang, 2015, Effects of camphorquinone on cytotoxicity, cell cycle regulation and prostaglandin E2 production of dental pulp cells: role of ROS, ATM/Chk2, MEK/ERK and hemeoxygenase-1, PLoS One, 10, e0143663, 10.1371/journal.pone.0143663
Duong, 2013, Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine, J. Cell Mol. Med., 17, 1261, 10.1111/jcmm.12101
Abdel-Fatah, 2015, Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer, Mol. Oncol., 9, 569, 10.1016/j.molonc.2014.10.013
Chen, 2016, Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells, Oncotarget, 7, 40362, 10.18632/oncotarget.9616
Zabludoff, 2008, AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies, Mol. Cancer Ther., 7, 2955, 10.1158/1535-7163.MCT-08-0492
Itamochi, 2014, Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary, Int. J. Gynecol. Cancer, 24, 61, 10.1097/IGC.0000000000000014
Bryant, 2014, Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers, BMC Cancer, 14, 570, 10.1186/1471-2407-14-570
He, 2011, Asperlin induces G(2)/M arrest through ROS generation and ATM pathway in human cervical carcinoma cells, Biochem Biophys. Res. Commun., 409, 489, 10.1016/j.bbrc.2011.05.032
Macip, 2006, Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G2 checkpoint, Oncogene, 25, 6037, 10.1038/sj.onc.1209629
Boutros, 2007, CDC25 phosphatases in cancer cells: key players? Good targets?, Nat. Rev. Cancer, 7, 495, 10.1038/nrc2169
Xiao, 2005, Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25C, Oncogene, 24, 6256, 10.1038/sj.onc.1208759
Brisson, 2007, Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone, Mol. Pharmacol., 71, 184, 10.1124/mol.106.028589
Okoh, 2015, Redox signalling to nuclear regulatory proteins by reactive oxygen species contributes to oestrogen-induced growth of breast cancer cells, Br. J. Cancer, 112, 1687, 10.1038/bjc.2014.586
Zhang, 2014, Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer, Cancer Res, 74, 6635, 10.1158/0008-5472.CAN-14-1916
Ward, 2014, p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress, PLoS One, 9, e87918, 10.1371/journal.pone.0087918
Wang, 2017, Autophagy substrate SQSTM1/p62 regulates chromatin ubiquitination during the DNA damage response, Autophagy, 13, 212, 10.1080/15548627.2016.1245262
Soussi, 2006, Locus-specific mutation databases: pitfalls and good practice based on the p53 experience, Nat. Rev. Cancer, 6, 83, 10.1038/nrc1783
Cheng, 2010, Mechanism of p53 stabilization by ATM after DNA damage, Cell Cycle, 9, 472, 10.4161/cc.9.3.10556
Maillet, 2012, Redox regulation of p53, redox effectors regulated by p53: a subtle balance, Antioxid. Redox Signal., 16, 1285, 10.1089/ars.2011.4434
Humpton, 2016, Regulation of cellular metabolism and hypoxia by p53, Cold Spring Harb. Perspect. Med, 6, 10.1101/cshperspect.a026146
Macip, 2003, Influence of induced reactive oxygen species in p53-mediated cell fate decisions, Mol. Cell Biol., 23, 8576, 10.1128/MCB.23.23.8576-8585.2003
Sablina, 2005, The antioxidant function of the p53 tumor suppressor, Nat. Med., 11, 1306, 10.1038/nm1320
Wanka, 2012, Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis, J. Biol. Chem., 287, 33436, 10.1074/jbc.M112.384578
Bensaad, 2006, TIGAR, a p53-inducible regulator of glycolysis and apoptosis, Cell, 126, 107, 10.1016/j.cell.2006.05.036
Shi, 2014, ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis, Cell Death Differ., 21, 612, 10.1038/cdd.2013.186
Drane, 2001, Reciprocal down-regulation of p53 and SOD2 gene expression-implication in p53 mediated apoptosis, Oncogene, 20, 430, 10.1038/sj.onc.1204101
Faraonio, 2006, p53 suppresses the Nrf2-dependent transcription of antioxidant response genes, J. Biol. Chem., 281, 39776, 10.1074/jbc.M605707200
Teng, 2018, ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB, Nat. Commun., 9, 4115, 10.1038/s41467-018-06586-3
Bravard, 2006, Redox regulation of human OGG1 activity in response to cellular oxidative stress, Mol. Cell Biol., 26, 7430, 10.1128/MCB.00624-06
Santos, 2007, Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria, Arch. Toxicol., 81, 495, 10.1007/s00204-006-0173-2
Jiang, 2008, Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons, Cancer Res., 68, 6425, 10.1158/0008-5472.CAN-08-1173
Ju, 2015, Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation, Mol. Cancer Ther., 14, 788, 10.1158/1535-7163.MCT-14-0420
Podratz, 2011, Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons, Neurobiol. Dis., 41, 661, 10.1016/j.nbd.2010.11.017
Yang, 2006, Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis, Clin. Cancer Res, 12, 5817, 10.1158/1078-0432.CCR-06-1037
Giurgiovich, 1997, Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure, Carcinogenesis, 18, 93, 10.1093/carcin/18.1.93
Choi, 2015, Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation, PLoS One, 10, e0135083, 10.1371/journal.pone.0135083
Gupta, 2012, Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy, Antioxid. Redox Signal, 16, 1295, 10.1089/ars.2011.4414
Riley, 1994, Free radicals in biology: oxidative stress and the effects of ionizing radiation, Int J. Radiat. Biol., 65, 27, 10.1080/09553009414550041
Miura, 1991, Role of glutathione in the intrinsic radioresistance of cell lines from a mouse squamous cell carcinoma, Radiat. Res., 126, 229, 10.2307/3577823
Ohta, 2008, Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth, Cancer Res., 68, 1303, 10.1158/0008-5472.CAN-07-5003
Shibata, 2008, Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy, Proc. Natl. Acad. Sci. USA, 105, 13568, 10.1073/pnas.0806268105
Shibata, 2008, Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer, Gastroenterology, 135, 1358, 10.1053/j.gastro.2008.06.082
Patwardhan, 2015, Spatio-temporal changes in glutathione and thioredoxin redox couples during ionizing radiation-induced oxidative stress regulate tumor radio-resistance, Free Radic. Res., 49, 1218, 10.3109/10715762.2015.1056180
Diehn, 2009, Association of reactive oxygen species levels and radioresistance in cancer stem cells, Nature, 458, 780, 10.1038/nature07733
Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu Rev. Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008
Janko, 2014, Redox modulation of HMGB1-related signaling, Antioxid. Redox Signal., 20, 1075, 10.1089/ars.2013.5179
Yang, 2010, A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release, Proc. Natl. Acad. Sci. USA, 107, 11942, 10.1073/pnas.1003893107
Schiraldi, 2012, HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4, J. Exp. Med., 209, 551, 10.1084/jem.20111739
Venereau, 2012, Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release, J. Exp. Med., 209, 1519, 10.1084/jem.20120189
Tsung, 2007, HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling, J. Exp. Med., 204, 2913, 10.1084/jem.20070247
Fan, 2007, Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling, J. Immunol., 178, 6573, 10.4049/jimmunol.178.10.6573
Tang, 2010, HMGB1 release and redox regulates autophagy and apoptosis in cancer cells, Oncogene, 29, 5299, 10.1038/onc.2010.261
Guerriero, 2011, DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity, J. Immunol., 186, 3517, 10.4049/jimmunol.1003267
Kazama, 2008, Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein, Immunity, 29, 21, 10.1016/j.immuni.2008.05.013
Hato, 2014, Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics, Clin. Cancer Res., 20, 2831, 10.1158/1078-0432.CCR-13-3141
Maemura, 2005, Reactive oxygen species are essential mediators in antigen presentation by Kupffer cells, Immunol. Cell Biol., 83, 336, 10.1111/j.1440-1711.2005.01323.x
Matsue, 2003, Generation and function of reactive oxygen species in dendritic cells during antigen presentation, J. Immunol., 171, 3010, 10.4049/jimmunol.171.6.3010
Garg, 2013, ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death, Autophagy, 9, 1292, 10.4161/auto.25399
Vandenberk, 2016, Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma, Oncoimmunology, 5, e1083669, 10.1080/2162402X.2015.1083669
Montero, 2012, Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer, Breast Cancer Res Treat., 132, 215, 10.1007/s10549-011-1889-0
Fidias, 2010, A randomized, open-label, phase III trial of nov-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC), J. Clin. Oncol., 28, 10.1200/jco.2010.28.18_suppl.lba7007
Cohen, 2010, A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer, Cancer Chemother. Pharmacol., 66, 287, 10.1007/s00280-009-1162-y
Barr, 2014, Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma, Blood, 124, 1259, 10.1182/blood-2014-04-570044
Wang, 2016, Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2alpha-ATF4-xCT pathway, Oncotarget, 7, 74132, 10.18632/oncotarget.12356
Nauman, 2018, Systematic review of Intravenous ascorbate in cancer clinical trials, Antioxidants, 7, 10.3390/antiox7070089
Ma, 2017, : polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway, Nat. Commun., 8, 1506, 10.1038/s41467-017-01647-5
Kwee, 2014, Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer, World J. Gastroenterol., 20, 1650, 10.3748/wjg.v20.i7.1650
Marengo, 2016, Redox Homeostasis and Cellular Antioxidant Systems: crucial Players in Cancer Growth and Therapy, Oxid. Med. Cell Longev., 2016, 6235641, 10.1155/2016/6235641
Fidias, 2010, Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer, J. Clin. Oncol., 28, 5116, 10.1200/JCO.2010.30.7074
Krasner, 2008, NOV-002 plus carboplatin in platinum-resistant ovarian cancer, J. Clin. Oncol., 26, 10.1200/jco.2008.26.15_suppl.5593
Moulder, 2010, A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer, Investig New Drugs, 28, 634, 10.1007/s10637-009-9273-1
Mathur, 2017, ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice, Nat. Genet., 49, 296, 10.1038/ng.3744
Anderson, 2002, Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy, Bone Marrow Transplant., 30, 135, 10.1038/sj.bmt.1703605
Mehta, 2009, Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial, Int J. Radiat. Oncol. Biol. Phys., 73, 1069, 10.1016/j.ijrobp.2008.05.068
Bradley, 2013, Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study, Int. J. Radiat. Oncol. Biol. Phys., 85, e55, 10.1016/j.ijrobp.2012.09.004
William, 2007, Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer, J. Thorac. Oncol., 2, 745, 10.1097/JTO.0b013e31811f4719
Polireddy, 2017, High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: mechanisms and a phase I/IIa study, Sci. Rep., 7, 17188, 10.1038/s41598-017-17568-8
Monti, 2012, Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer, PLoS One, 7, e29794, 10.1371/journal.pone.0029794